Harvard Medical School

An advancing wave of new candidates, spanning diverse modalities, converges with push for surrogate endpoint status

The Massachusetts-based company launched a microRNA-based liquid biopsy test for endometriosis, with an eye toward disease monitoring and drug development

San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue

Early clinical data show efficacy signals that appear to improve on existing therapies in GI cancer settings

BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity